The government agency released its latest guidance this week.
11 questions for the GW CEO on the watershed moment.
The approval answers one question but raises others.
Two FDA guidance documents aim to help pharma companies show the value of their drugs to payers beyond what's included in FDA labeling.
Legalization of the drug for medical use is already having an impact on prescription patterns. But for patients and doctors alike, there are a lot of unanswered questions.
As of May 25, Europe's groundbreaking General Data Protection Regulation (GDPR) will take effect, fundamentally changing the way businesses and government agencies deal with personal data.
The pace may even pick up again this year.
The research will also cover topics including disease awareness ads.
Although if approved, it's not likely to launch in the U.S. for quite some time.
Once Attorney General Jeff Sessions reversed the Cole memo, NORML began applying pressure both locally and nationally for changes in marijuana laws.
The first year of the Trump administration was kind to pharma, but it might not be so fortunate in 2018.
Alex Azar, previously a senior executive at Eli Lilly, proposed granting Part B the authority to negotiate lower prices.
The FDA's Office of Prescription Drug Promotion issued a warning letter to Amherst Pharmaceuticals and Magna Pharmaceutical.
A mini wave of state-level rule-making has thrust the issue of restrictions on pharma payments to medical professionals back into the spotlight.
The OPDP has only issued two letters in 2017, compared to 11 last year.